24

mhlw · 0.3% FGF-2 (0/0) 60 80 100 p=O.021 40 Kitamura et al.PLoS ONE 2: e2611, 60 50 30 20 10 Zheng et al. TISSUE ENGINEERING: 52* Part A 2009 . Adipose ADSCf*n J) ADSC (4—6 x

  • Upload
    others

  • View
    0

  • Download
    0

Embed Size (px)

Citation preview

Page 1: mhlw · 0.3% FGF-2 (0/0) 60 80 100 p=O.021 40 Kitamura et al.PLoS ONE 2: e2611, 60 50 30 20 10 Zheng et al. TISSUE ENGINEERING: 52* Part A 2009 . Adipose ADSCf*n J) ADSC (4—6 x
Page 2: mhlw · 0.3% FGF-2 (0/0) 60 80 100 p=O.021 40 Kitamura et al.PLoS ONE 2: e2611, 60 50 30 20 10 Zheng et al. TISSUE ENGINEERING: 52* Part A 2009 . Adipose ADSCf*n J) ADSC (4—6 x
Page 3: mhlw · 0.3% FGF-2 (0/0) 60 80 100 p=O.021 40 Kitamura et al.PLoS ONE 2: e2611, 60 50 30 20 10 Zheng et al. TISSUE ENGINEERING: 52* Part A 2009 . Adipose ADSCf*n J) ADSC (4—6 x
Page 4: mhlw · 0.3% FGF-2 (0/0) 60 80 100 p=O.021 40 Kitamura et al.PLoS ONE 2: e2611, 60 50 30 20 10 Zheng et al. TISSUE ENGINEERING: 52* Part A 2009 . Adipose ADSCf*n J) ADSC (4—6 x
Page 5: mhlw · 0.3% FGF-2 (0/0) 60 80 100 p=O.021 40 Kitamura et al.PLoS ONE 2: e2611, 60 50 30 20 10 Zheng et al. TISSUE ENGINEERING: 52* Part A 2009 . Adipose ADSCf*n J) ADSC (4—6 x
Page 6: mhlw · 0.3% FGF-2 (0/0) 60 80 100 p=O.021 40 Kitamura et al.PLoS ONE 2: e2611, 60 50 30 20 10 Zheng et al. TISSUE ENGINEERING: 52* Part A 2009 . Adipose ADSCf*n J) ADSC (4—6 x
Page 7: mhlw · 0.3% FGF-2 (0/0) 60 80 100 p=O.021 40 Kitamura et al.PLoS ONE 2: e2611, 60 50 30 20 10 Zheng et al. TISSUE ENGINEERING: 52* Part A 2009 . Adipose ADSCf*n J) ADSC (4—6 x
Page 8: mhlw · 0.3% FGF-2 (0/0) 60 80 100 p=O.021 40 Kitamura et al.PLoS ONE 2: e2611, 60 50 30 20 10 Zheng et al. TISSUE ENGINEERING: 52* Part A 2009 . Adipose ADSCf*n J) ADSC (4—6 x
Page 9: mhlw · 0.3% FGF-2 (0/0) 60 80 100 p=O.021 40 Kitamura et al.PLoS ONE 2: e2611, 60 50 30 20 10 Zheng et al. TISSUE ENGINEERING: 52* Part A 2009 . Adipose ADSCf*n J) ADSC (4—6 x
Page 10: mhlw · 0.3% FGF-2 (0/0) 60 80 100 p=O.021 40 Kitamura et al.PLoS ONE 2: e2611, 60 50 30 20 10 Zheng et al. TISSUE ENGINEERING: 52* Part A 2009 . Adipose ADSCf*n J) ADSC (4—6 x
Page 11: mhlw · 0.3% FGF-2 (0/0) 60 80 100 p=O.021 40 Kitamura et al.PLoS ONE 2: e2611, 60 50 30 20 10 Zheng et al. TISSUE ENGINEERING: 52* Part A 2009 . Adipose ADSCf*n J) ADSC (4—6 x
Page 12: mhlw · 0.3% FGF-2 (0/0) 60 80 100 p=O.021 40 Kitamura et al.PLoS ONE 2: e2611, 60 50 30 20 10 Zheng et al. TISSUE ENGINEERING: 52* Part A 2009 . Adipose ADSCf*n J) ADSC (4—6 x
Page 13: mhlw · 0.3% FGF-2 (0/0) 60 80 100 p=O.021 40 Kitamura et al.PLoS ONE 2: e2611, 60 50 30 20 10 Zheng et al. TISSUE ENGINEERING: 52* Part A 2009 . Adipose ADSCf*n J) ADSC (4—6 x
Page 14: mhlw · 0.3% FGF-2 (0/0) 60 80 100 p=O.021 40 Kitamura et al.PLoS ONE 2: e2611, 60 50 30 20 10 Zheng et al. TISSUE ENGINEERING: 52* Part A 2009 . Adipose ADSCf*n J) ADSC (4—6 x
Page 15: mhlw · 0.3% FGF-2 (0/0) 60 80 100 p=O.021 40 Kitamura et al.PLoS ONE 2: e2611, 60 50 30 20 10 Zheng et al. TISSUE ENGINEERING: 52* Part A 2009 . Adipose ADSCf*n J) ADSC (4—6 x
Page 16: mhlw · 0.3% FGF-2 (0/0) 60 80 100 p=O.021 40 Kitamura et al.PLoS ONE 2: e2611, 60 50 30 20 10 Zheng et al. TISSUE ENGINEERING: 52* Part A 2009 . Adipose ADSCf*n J) ADSC (4—6 x
Page 17: mhlw · 0.3% FGF-2 (0/0) 60 80 100 p=O.021 40 Kitamura et al.PLoS ONE 2: e2611, 60 50 30 20 10 Zheng et al. TISSUE ENGINEERING: 52* Part A 2009 . Adipose ADSCf*n J) ADSC (4—6 x
Page 18: mhlw · 0.3% FGF-2 (0/0) 60 80 100 p=O.021 40 Kitamura et al.PLoS ONE 2: e2611, 60 50 30 20 10 Zheng et al. TISSUE ENGINEERING: 52* Part A 2009 . Adipose ADSCf*n J) ADSC (4—6 x
Page 19: mhlw · 0.3% FGF-2 (0/0) 60 80 100 p=O.021 40 Kitamura et al.PLoS ONE 2: e2611, 60 50 30 20 10 Zheng et al. TISSUE ENGINEERING: 52* Part A 2009 . Adipose ADSCf*n J) ADSC (4—6 x
Page 20: mhlw · 0.3% FGF-2 (0/0) 60 80 100 p=O.021 40 Kitamura et al.PLoS ONE 2: e2611, 60 50 30 20 10 Zheng et al. TISSUE ENGINEERING: 52* Part A 2009 . Adipose ADSCf*n J) ADSC (4—6 x
Page 21: mhlw · 0.3% FGF-2 (0/0) 60 80 100 p=O.021 40 Kitamura et al.PLoS ONE 2: e2611, 60 50 30 20 10 Zheng et al. TISSUE ENGINEERING: 52* Part A 2009 . Adipose ADSCf*n J) ADSC (4—6 x
Page 22: mhlw · 0.3% FGF-2 (0/0) 60 80 100 p=O.021 40 Kitamura et al.PLoS ONE 2: e2611, 60 50 30 20 10 Zheng et al. TISSUE ENGINEERING: 52* Part A 2009 . Adipose ADSCf*n J) ADSC (4—6 x
Page 23: mhlw · 0.3% FGF-2 (0/0) 60 80 100 p=O.021 40 Kitamura et al.PLoS ONE 2: e2611, 60 50 30 20 10 Zheng et al. TISSUE ENGINEERING: 52* Part A 2009 . Adipose ADSCf*n J) ADSC (4—6 x
Page 24: mhlw · 0.3% FGF-2 (0/0) 60 80 100 p=O.021 40 Kitamura et al.PLoS ONE 2: e2611, 60 50 30 20 10 Zheng et al. TISSUE ENGINEERING: 52* Part A 2009 . Adipose ADSCf*n J) ADSC (4—6 x